Medical device company AirXpanders Inc (ASX:AXP) reported on Friday the launch of a co-marketing agreement to introduce Radformation Inc's EZFluence software to US radiation oncology departments.

Through the co-marketing agreement, AirXpanders' sales personnel will launch the EZFluence software to US radiation oncology departments, who are treating a growing number of patients with the AeroForm Tissue Expander System.

This partnership is expected to improve acceptance of the AeroForm Expander by significantly improving the workflow required to develop radiation treatment plans. It expects radiation oncology departments to benefit from the intelligent automation of radiation therapy treatment planning for breast reconstruction patients.

According to Radformation, the EZFluence is US FDA cleared software and available since 2017. It is straightforward and easy to adopt and use. With a rapidly growing installed base, a growing number of radiation oncologists and medical physicists are utilising the system and experiencing its productivity and improvements .

Throughout 2019, the companies will plan, collaborate and educate at key Radiation Oncology and Medical Physics society meetings .